- Powder
- Suspension
- Tablet
- Eye drops
- Intravenous preparation
Ciprofloxacin Market Size was valued at USD x million in 2022 and is poised to grow at a 6.9% CAGR from 2023 to 2029. Ciprofloxacin is one of the broad-spectrum antibiotics for the drug class quinolone antibiotic. To maintain the antibiotic's effectiveness, the antibiotic Ciprofloxacin is largely employed to stop the growth of bacteriophages that are resistant to it. Only bacterial illnesses are treated with the medication ciprofloxacin; viral infections are not affected by it. The Urinary Tract Infections segment anticipated to grow at significant CAGR over the forecast years owing to Due to differences in anatomy, women are more likely than men to get urinary tract infections. In their lifetimes, many women get urinary tract infections more than once. According to some research, there are 150 million cases of urinary tract infections worldwide. Additionally, about 11% of women see a doctor for treatment of a UTI once a year. Moreover, competitors are focusing on launching and acquisition to maintain growth in the market. For instance, In December 2002 FDA Approves Once-Daily Cipro XR for the Treatment of Uncomplicated Urinary Tract Infections (UTIs). Increase in prevalence of bacterial infection such as (UTI), eye infections, among others is anticipated to create lucrative growth opportunities for the ciprofloxacin market.
Ciprofloxacin Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.9%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Ciprofloxacin Market Dynamics
The incidence of kidney infections and eye infections is one of the main factors propelling the Ciprofloxacin market's expansion. due to higher efficacy of Ciprofloxacin in treating the infections associated with the excretory system especially renal and urinary system. In June 2018 the US FDA warned the manufacturers and issued guidelines for the labeling black box warning mentioning safety warnings for the fluoroquinolones category of medicines. Considering the drug's negative effects on tendons and skin in paediatric and geriatric patients. It is projected that there would be a significant increase in demand for ciprofloxacin because of the requirement for broad spectrum antibiotics in the global pharmaceutical market.
North-America Got Significant Share
Ciprofloxacin Market Regional Share
The ciprofloxacin market in North America is likely to hold the highest revenue share of in 2023 and same trend is expected over the forecast period although there have been advancements in pharmaceutical labelling, a well-developed healthcare infrastructure, high preference for prevention, increased awareness of safe drug usage, and strict government regulations, the global Ciprofloxacin market's growth trajectory in North America has been constrained.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The ciprofloxacin market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Ciprofloxacin Market Segmentation
By Dosage Form
By Application
- Urinary Tract Infections
- Lower Respiratory Infections
- Nosocomial Pneumonia
- Skin Structure Infections
- Bone and Joint Infections
- Intra-Abdominal Infection
- Acute Sinusitis
- Chronic Bacterial Prostatitis
By Distribution Channel
- Hospitals Pharmacies
- Retail pharmacies
- Drug stores
- Online pharmacies
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The key segments covered in the restless leg’s syndrome market are technology, components, application, and end-users.
The ciprofloxacin market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The ciprofloxacin market key players are Novartis International AG, Allergan plc, Merck & Co Inc, Cipla Limited, Bayer AG, Cadila Healthcare, Glenmark Pharmaceuticals, Hexal, Sanofi Synthelabo, Pfleger, Mylan Laboratories Ltd
| 1.Executive Summary |
| 2.Global Ciprofloxacin Market Introduction |
| 2.1.Global Ciprofloxacin Market - Taxonomy |
| 2.2.Global Ciprofloxacin Market - Definitions |
| 2.2.1.Dosage Form |
| 2.2.2.Application |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Ciprofloxacin Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Ciprofloxacin Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Ciprofloxacin Market By Dosage Form, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Powder |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Suspension |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Tablet |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Eye drops |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Intravenous preparation |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Ciprofloxacin Market By Application , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Urinary Tract Infections |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lower Respiratory Infections |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Nosocomial Pneumonia |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Skin Structure Infections |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Bone and Joint Infections |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Intra-Abdominal Infection |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Acute Sinusitis |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 6.8. Chronic Bacterial Prostatitis |
| 6.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.8.3. Market Opportunity Analysis |
| 7.Global Ciprofloxacin Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospitals Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Drug stores |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Online pharmacies |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Ciprofloxacin Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Ciprofloxacin Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Dosage Form Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Powder |
| 9.1.2.Suspension |
| 9.1.3.Tablet |
| 9.1.4.Eye drops |
| 9.1.5.Intravenous preparation |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Urinary Tract Infections |
| 9.2.2.Lower Respiratory Infections |
| 9.2.3.Nosocomial Pneumonia |
| 9.2.4.Skin Structure Infections |
| 9.2.5.Bone and Joint Infections |
| 9.2.6.Intra-Abdominal Infection |
| 9.2.7.Acute Sinusitis |
| 9.2.8.Chronic Bacterial Prostatitis |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals Pharmacies |
| 9.3.2.Retail pharmacies |
| 9.3.3.Drug stores |
| 9.3.4.Online pharmacies |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Ciprofloxacin Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Dosage Form Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Powder |
| 10.1.2.Suspension |
| 10.1.3.Tablet |
| 10.1.4.Eye drops |
| 10.1.5.Intravenous preparation |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Urinary Tract Infections |
| 10.2.2.Lower Respiratory Infections |
| 10.2.3.Nosocomial Pneumonia |
| 10.2.4.Skin Structure Infections |
| 10.2.5.Bone and Joint Infections |
| 10.2.6.Intra-Abdominal Infection |
| 10.2.7.Acute Sinusitis |
| 10.2.8.Chronic Bacterial Prostatitis |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals Pharmacies |
| 10.3.2.Retail pharmacies |
| 10.3.3.Drug stores |
| 10.3.4.Online pharmacies |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Ciprofloxacin Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Dosage Form Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Powder |
| 11.1.2.Suspension |
| 11.1.3.Tablet |
| 11.1.4.Eye drops |
| 11.1.5.Intravenous preparation |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Urinary Tract Infections |
| 11.2.2.Lower Respiratory Infections |
| 11.2.3.Nosocomial Pneumonia |
| 11.2.4.Skin Structure Infections |
| 11.2.5.Bone and Joint Infections |
| 11.2.6.Intra-Abdominal Infection |
| 11.2.7.Acute Sinusitis |
| 11.2.8.Chronic Bacterial Prostatitis |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals Pharmacies |
| 11.3.2.Retail pharmacies |
| 11.3.3.Drug stores |
| 11.3.4.Online pharmacies |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Ciprofloxacin Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Dosage Form Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Powder |
| 12.1.2.Suspension |
| 12.1.3.Tablet |
| 12.1.4.Eye drops |
| 12.1.5.Intravenous preparation |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Urinary Tract Infections |
| 12.2.2.Lower Respiratory Infections |
| 12.2.3.Nosocomial Pneumonia |
| 12.2.4.Skin Structure Infections |
| 12.2.5.Bone and Joint Infections |
| 12.2.6.Intra-Abdominal Infection |
| 12.2.7.Acute Sinusitis |
| 12.2.8.Chronic Bacterial Prostatitis |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals Pharmacies |
| 12.3.2.Retail pharmacies |
| 12.3.3.Drug stores |
| 12.3.4.Online pharmacies |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Ciprofloxacin Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Dosage Form Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Powder |
| 13.1.2.Suspension |
| 13.1.3.Tablet |
| 13.1.4.Eye drops |
| 13.1.5.Intravenous preparation |
| 13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Urinary Tract Infections |
| 13.2.2.Lower Respiratory Infections |
| 13.2.3.Nosocomial Pneumonia |
| 13.2.4.Skin Structure Infections |
| 13.2.5.Bone and Joint Infections |
| 13.2.6.Intra-Abdominal Infection |
| 13.2.7.Acute Sinusitis |
| 13.2.8.Chronic Bacterial Prostatitis |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals Pharmacies |
| 13.3.2.Retail pharmacies |
| 13.3.3.Drug stores |
| 13.3.4.Online pharmacies |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Novartis International AG |
| 14.2.2.Allergan plc |
| 14.2.3.Merck & Co Inc |
| 14.2.4.Cipla Limited |
| 14.2.5.Bayer AG |
| 14.2.6.Cadila Healthcare |
| 14.2.7.Glenmark Pharmaceuticals |
| 14.2.8.Hexal |
| 14.2.9.Sanofi Synthelabo |
| 14.2.10.Pfleger |
| 14.2.11.Mylan Laboratories Ltd |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Novartis International AG
- Allergan plc
- Merck & Co Inc
- Cipla Limited
- Bayer AG
- Cadila Healthcare
- Glenmark Pharmaceuticals
- Hexal
- Sanofi Synthelabo
- Pfleger
- Mylan Laboratories Ltd